SCHEMBL5077786

SCHEMBL5077786

c1ccc(-c2ccn(-c3cccc(-c4cccnc4)n3)c2)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.59
COMT P21964 3/20 0.48
GRM5 P41594 3/20 0.45
TSHR P16473 2/20 0.44
NPC1 O15118 2/20 0.44
TP53 P04637 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
PKM P14618 1/20 0.44
MAPT P10636 1/20 0.43
CYP3A4 P08684 4/20 0.43
CYP2D6 P10635 3/20 0.43
CYP1A2 P05177 2/20 0.43
HSD17B10 Q99714 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 4/20 0.43
CYP2E1 P05181 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5669546 0.80 CYP2A6 (0.59) CYP2A6GRM5TSHRNPC1TP53
SCHEMBL5078491 0.80 GRM5 (0.60) CYP2A6COMTGRM5TSHRNPC1
SCHEMBL5077794 0.79 GRM5 (0.49) CYP2A6COMTGRM5NPC1TP53
SCHEMBL2732909 0.78 CYP2A6 (0.50) CYP2A6COMTTSHRNPC1TP53
[2,3'']Bipyridinyl SCHEMBL29389597 0.77 CYP2A6 (1.00) CYP2A6TSHRNPC1TP53RAB9A
[2,3'']Bipyridinyl SCHEMBL29360744 0.77 CYP2A6 (1.00) CYP2A6TSHRNPC1TP53RAB9A
[2,3'']Bipyridinyl SCHEMBL29486847 0.77 CYP2A6 (1.00) CYP2A6TSHRNPC1TP53RAB9A
[2,3'']Bipyridinyl SCHEMBL998601 0.77 CYP2A6 (1.00) CYP2A6TSHRNPC1TP53RAB9A
SCHEMBL10020874 0.76 CYP2A6 (0.76) CYP2A6GRM5TSHRNPC1TP53
[2,3'']Bipyridinyl SCHEMBL1418333 0.75 CYP2A6 (0.96) CYP2A6TSHRNPC1TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7393959-B2 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 MERCK & CO. INC. (US) 2008-07-01 US claimed
EP-1613265-A4 DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-02-14 EP claimed
US-20060193926-A1 Di-arylsubstituted pyrrole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2006-08-31 US claimed
EP-1613265-A2 DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-01-11 EP claimed
WO-2004089308-A2 DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2004-10-21 WO claimed
US-7393959-B2 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 MERCK & CO. INC. (US) 2008-07-01 US disclosed
EP-1613265-A4 DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-02-14 EP disclosed
US-20060193926-A1 Di-arylsubstituted pyrrole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2006-08-31 US disclosed
EP-1613265-A2 DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-01-11 EP disclosed
WO-2004089308-A2 DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060193926-A1 Di-arylsubstituted pyrrole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2B CYP2A6 1537/4885COMT 753/4885GRM5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.